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ABSTRACT 
Background - The great clinical potential of myocardial β-AR imaging has been 
shown by recent studies evaluating the -AR specific, non selective agent [11C]-
CGP12177 in the setting of idiopathic dilated cardiomyopathy and myocardial 
infarction. However, the short half-life of 
11
C hampers the potential of [
11
C]-
CGP12177 for routine clinical use. AMI9 is an analog of the -adrenoceptor 
ligand practolol that can readily be labeled using radioactive isotopes of iodine. 
The present study was aimed at characterizing the in vitro, ex vivo, and in vivo -
AR binding properties of [
125
I]-AMI9.   
Methods and Results – Newborn rat cardiomyocytes were used for saturation 
and kinetic binding assays as well as for displacement and competition 
experiments. Isolated perfused rat hearts were used to evaluate the 
pharmacological activity of AMI9. The in vivo kinetics of [
125
I]-AMI9 were 
studied using biodistribution experiments in mice. [125I]-AMI9 displayed high 
specific affinity for -AR with no -AR subtype selectivity (KD, 5.6±0.3 nM; 
Bmax, 231±7 fmol/mg of protein). AMI9 potently inhibited the inotropic effects 
of isoproterenol. The early in vivo cardiac and lung activities of [
125
I]-AMI9 
compared favorably with those of the clinically validated tracer CGP12177.  
Conclusions – Iodine-labeled AMI9 is a promising agent for the molecular 
imaging of myocardial -AR density.  
 
Key Words: basic science - radiopharmaceuticals – receptor imaging 
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ABBREVIATIONS 
 
AMI9, [(R,S)-(1-[4-(-4-iodobut-3-enecarboxamido)phenoxy]-3-
isopropylaminopropan-2-ol)] 
AR, Adrenergic Receptors 
DUR, Differential Uptake Ratio 
HPLC, High Performance Liquid Chromatography 
ICYP, Iodocyanopindolol 
LV, Left Ventricle 
NE, Norepinephrine 
NRCM, Newborn Rat Cardiomyocytes 
RBA, Relative binding Affinity 
SNS, Sympathetic Nervous System 
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INTRODUCTION 
The cardiac SNS affects fundamental features of cardiac function such as systolic 
contraction, diastolic relaxation, myocardial blood flow, and heart rate through 
pre-synaptic release of the neurotransmitter NE by sympathetic neurons and post-
synaptic binding of NE to α- and β- AR on cardiac cells. Importantly, cardiac SNS 
dysfunction has been recognized to play major roles in the development of LV 
dysfunction, heart failure, and diabetic heart disease progression [1, 2]. 
Pathophysiological modifications in β-AR density have been observed in a 
number of cardiac conditions [3] and more specifically in heart failure [1] and 
diabetic heart disease [2]. The non-selective, β-AR specific ligand [11C]-
CGP12177 represents the most studied agent for the non invasive in vivo 
assessment of β-AR density in clinical settings such as non-ischemic 
cardiomyopathy and myocardial infarction [4, 5].  [
11
C]-CGP12177 predicted the 
improvement of cardiac function in patients with idiopathic dilated 
cardiomyopathy after long-term carvedilol treatment whereas dobutamine stress 
echocardiography did not [6], and Gaemperli et al. found that reduced myocardial 
-AR density early after myocardial infarction was associated with the incidence 
of congestive heart failure on long-term follow-up [7]. In addition, recent studies 
have emphasized the clinical importance of assessing the presence of a potential 
mismatch in the cardiac SNS using agents targeted at the pre- and post-synaptic 
function [8, 9]. Although such studies have provided proof-of-concept that β-AR 
imaging has great potential clinical interest by itself or in combination with a pre-
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synaptic agent, the development of an [
11
C]-labelled PET imaging agent is limited 
by the extremely short half-life of the isotope (20.4 min).  
-blockers labeled with radioactive isotopes of iodine and therefore suitable for 
SPECT imaging have not proven successful so far due to either suboptimal 
affinity for -AR or high nonspecific binding associated with high lipophilicity 
[10-13]. Studies performed with iodinated analogues of CGP-12177 also yielded 
negative results [14]. The aim of the present study was to perform the in vitro, ex 
vivo, and in vivo preclinical evaluation of AMI9, an analog of the -AR ligand 
practolol, for the molecular nuclear imaging of β-AR density.  
 
MATERIALS & METHODS 
 
The chemical structure of AMI9 is presented in Figure 1. Primary cultures of 
NRCM were prepared and used as previously described [15] to perform 
radioligand displacement experiments and binding assays while isolated and 
perfused rat hearts were used to determine AMI9 & AMI9S pharmacological 
activities and swiss mice were used to evaluate [
125
I]-AMI9, [
3
H]-CGP-12177, 
and [
125
I]-ICYP in vivo biodistribution. Full details regarding these procedures as 
well as those used for AMI9 & AMI9S chemical synthesis, radiolabeling, and 
determination of lipophilicity are provided in the supplementary data file. All 
experimental procedures were in accordance with Institutional Guidelines for 
Care and Use of Laboratory Animals. 
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RESULTS 
 
Radioligand displacement experiments 
Competition curves between [3H]-CGP-12177 and AMI9 or AMI9S are shown in 
Figure 2. Both sets of data were best fitted monophasically, indicating a single 
class of affinity for -AR. The competition curves between [3H]-CGP-12177 and 
alprenolol (), atenolol (1), metoprolol (1), pindolol (), propranolol () and 
timolol () presented similar profiles. Corresponding KI, IC50 and RBA values 
are shown in Table 1. The rank order of increasing RBA was atenolol < 
metoprolol < AMI9S < AMI9 < propranolol < alprenolol < timolol < pindolol. 
 
Binding assays 
[125I]-AMI9 and [125I]-AMI9S Scatchard curves for NRCM -AR binding are 
shown in Figure 3. Bmax values with [125I]-AMI9 (KD: 5.6 ± 0.3 nM) and 
[125I]-AMI9S (KD: 3.1 ± 0.2 nM) were 231 ± 7 fmol/mg prot, and 223 ± 7 
fmol/mg prot, respectively. Plasmic membrane -AR density was estimated at 85 
± 6 fmol/mg prot using [3H]-CGP-12177 (KD: 1.0 ± 0.1 nM) while total -AR 
density as estimated using [125I]-ICYP reached 290 ± 20 fmol/mg prot (KD: 0.4 
± 0.0 nM). In accordance with results from saturation experiments, the KD values 
of [125I]-AMI9 and [125I]-AMI9S as obtained from the analysis of the kinetics 
curves were 4.5 nM and 2.6 nM, respectively (data not shown). 
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The results from competition experiments aimed at assessing the specificity and 
selectivity of [125I]-AMI9 and [125I]-AMI9S binding are shown in Table 2. Both 
[125I]-AMI9 and [125I]-AMI9S did not bind to muscarinic receptors as shown 
from the lack of effect of atropine. Conversely, 1-, 2-, 1- and 2-selective 
blockers competed with [125I]-AMI9 and [125I]-AMI9S binding. The biphasic 
profiles observed in the presence of CGP-20712A, ICI 118551 and prazosin 
indicated subtype selectivity although yohimbine addition did not lead to a 
biphasic competition curve. At the highest concentration of competitor, AMI9 and 
AMI9S binding inhibition by CGP-20712A and ICI 118551 was similar to that 
observed with propranolol. Prazosin and phentolamine also had a comparable 
potential for AMI9 & AMI9S binding inhibition. 
 
Pharmacological activity 
Propranolol, AMI9 and AMI9S inhibited the isoproterenol-induced increase in 
dP/dtmax of isolated perfused rat hearts in a dose-dependent manner (Table 3). A 
significant inhibition of isoproterenol-induced increase in contractility was 
observed with 1 nM AMI9 and 10 nM AMI9S or propranolol. The concentrations 
of propranolol, AMI9, and AMI9S required to reach half-maximal inhibition of 
the isoproterenol-induced increase in dP/dtmax (CID50) were 5.9 ± 0.8 nM, 1.4 ± 
0.5 nM and 3.7 ± 2.1 nM, respectively. 
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Lipophilicity 
The log(P) value of AMI9 was 0.613. The retention coefficient (k') value of AMI9 
(1.11) was lower than that of the lipophilic compound propranolol (1.43), 
comparable to that of the moderately lipophilic CGP-20712A (0.97) and higher 
than those of the hydrophilic compounds oxprenolol (0.78), CGP-12177 (0.13), 
and practolol (0.06).  
 
Biodistribution in mice 
The biodistributions of [125I]-AMI9, [3H]-CGP-12177 and [125I]-ICYP are 
presented in Tables 4, 5 and 6, respectively.  
[125I]-AMI9 - Blood tracer activity was maximal immediately following 
injection (0.5 min, DUR: 3.1 ± 0.1) and then rapidly decreased to stabilize at ~1.2. 
In contrast, the cardiac radioactivity initially accumulated and peaked at 2 min p.i. 
(DUR: 5.3 ± 0.5) prior to decreasing (120 min-DUR: 0.5 ± 0.1).  Pulmonary 
activity was 2 to 6-fold higher than myocardial activity at all time points. The 
tracer was excreted predominantly though the kidneys with significant 
involvement of the hepatic route as well. Low [
125
I]-AMI9 activities were 
observed in the brain, muscle and fat (DUR range: brain, 0.1-0.3; muscle 0.3-1.2; 
fat, 0.1-0.5). 
[3H]-CGP-12177 - Blood tracer activity peaked immediately following 
injection (0.5 min, DUR: 2.2 ± 0.2) and decreased slowly thereafter to reach a 
minimal value of 0.6 ± 0.1 at 120 min p.i. The cardiac activity followed 
approximately the same kinetic pattern. Early pulmonary activity was comparable 
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to that observed following injection of [
125
I]-AMI9 but remained elevated at later 
time points with lung uptake typically being 5- to 10-fold higher than cardiac 
uptake. The renal and hepatic routes were equally involved in tracer excretion and 
liver activity was lower than that of [
125
I]-AMI9. Finally, [3H]-CGP-12177 
exhibited low brain, muscle and fat activities (DUR range: brain, 0.0 - 0.2; 
muscle, 0.4 - 0.9; fat, 0.1 - 0.6). 
[125I]-ICYP - Blood tracer activity remained stable over time with DUR 
values within the 1.7 ± 0.5 and 2.7 ± 0.1 range. One-min cardiac radioactivity 
reached a maximum value similar to that of [125I]-AMI 9 and stabilized at a DUR 
of ~2.1 from 15 min p.i.. Pulmonary uptake was 5 to 20-fold higher than cardiac 
uptake at all time points and did not decrease significantly over time. No hepatic 
and renal accumulation of [
125
I]-ICYP was observed. Finally, brain, muscle and 
fat also displayed low [
125
I]-ICYP activities (DUR range: 0.07 - 0.12, 0.5 - 0.8 and 
0.0 - 0.6, respectively). 
 
DISCUSSION 
The affinity (KA) of radiolabeled -AR ligands for -ARs should approximate 
109 M-1 [16], and the compounds should display -blocker properties without 
inner sympathomimetic activity in order to form stable complexes with -AR. 
As observed for most -blockers, the asymmetry of the carbon carrying the 
secondary alcohol function of the AMI9 compound generates two optical 
enantiomers R and S. Since the S enantiomer of aryloxypropanolamines is 
generally better recognized by -AR than the R enantiomer, an original synthesis 
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pathway was developed for the obtention of AMI9S. The results from the present 
study indicated that [
123
I]-AMI9 and [
123
I]-AMI9S displayed high affinities for -
AR in vitro and ex vivo as well as in vivo kinetics suitable for non invasive cardiac 
imaging following intravenous injection. 
In vitro binding experiments using the reference -AR radioligands [3H]-CGP-
12177 and [125I]-ICYP were performed to validate the NRCM model. The KD 
value for CGP-12177 (1.0 ± 0.1 nM) was in accordance with data obtained on rat 
intact cardiac myocytes (from 0.38 ± 0.03 nM to 3 ± 1 nM) [17] and the Bmax (85 
± 6 fmol/mg prot) was close to that observed for plasma membrane -AR by 
Yonemochi et al. (118 ± 18 fmol/mg prot) [18]. The KD value for ICYP (0.4 ± 0.0 
nM) was found to be higher by approximately one order of magnitude than values 
generally observed in the rat heart (22-29 pM) [19] while Bmax (290 ± 20 
fmol/mg prot) was similar to that observed by Karliner et al. for the total amount 
of -AR in a similar experimental model (260 ± 71 fmol/mg prot) [20]. 
[3H]-CGP-12177 displacement assays on NRCM allowed the comparison of RBA 
values for AMI9 and AMI9S with those of well-known -blockers. The rank 
order of increasing affinity for -AR was in overall accordance with previously 
published values [21]. RBA values of AMI9 and AMI9S were intermediary 
between those of metoprolol and propranolol. As the latter has an affinity 
considered as minimal for a potential -AR SPECT radioligand (KD from 0.76 to 
6 nM) [16, 22, 23], the affinity of AMI9 and AMI9S is therefore suitable for use 
as -AR SPECT ligands. Saturation and kinetic binding studies gave similar KD 
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values for AMI9 (5.6 ± 0.3 nM vs 4.5 nM, respectively) and AMI9S (3.1 ± 0.2 vs 
2.6 nM, respectively). Affinity ratios between AMI9S and AMI9 (1.64, 1.79 and 
1.75 depending on the binding study) were ~ 2 (theoretical ratio) and therefore 
confirmed the expected better activity of the S enantiomer. Finally, the two-phase 
profiles of the competition curves between CGP-20712A or ICI 118551 and 
AMI9 or AMI9S provided evidence that AMI9 and AMI9S bind to both 1- and 
2-AR. In addition, AMI9 and AMI9S poorly discriminated between -AR 
subtypes as indicated by the results obtained with the one-site model used to fit 
the corresponding Scatchard curves. The Bmax values of AMI9 and AMI9S 
relative to NRCM -AR were found to be identical, as expected for a racemic 
mixture in which the S-enantiomer only binds to receptors. Bmax values of both 
radioligands were therefore intermediary between those of [3H]-CGP-12177 and 
[125I]-ICYP, indicating that AMI9 bound not only to externalized -AR but also 
to intracellular -AR.  
These results were in accordance with the moderate lipophilicity of AMI9, whose 
partition coefficient (log(P) = 0.61) was intermediary between that of CGP-12177 
and ICYP (log(P) = -0.52 and 1.26, respectively) [24]. HPLC analysis confirmed 
the moderate lipophilic nature of AMI9, close to that of oxprenolol and CGP-
20712A. AMI9 and AMI9S therefore appear well suited for those pathologies 
such as chronic heart failure in which global down-regulation of –adrenoceptor 
expression occurs whereas their potential for diseases in which membrane 
receptors are being internalized will require further evaluation. 
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Results from specificity studies indicated that AMI9 and AMI9S bound to both - 
and -AR. Specificity ratios for CGP-20712A, ICI 118551 and prazosin from the 
present study were similar to those previously published. Indeed, 1:2 ratios for 
CGP-20712A (580:1 and 380:1) were close to those described by Birnbaumer et 
al. (845:1) [25]. Those for ICI 118551 (1:406 and 1:116) reflect the differences in 
the published ratios for this agent (1:54, 1:123, 1:225) [25-27], while the 1:2 
ratios for prazosin (3220:1 and 450:1) were around the generally observed relative 
values (1000:1 or 1590:1) [28, 29]. Human -AR myocardial expression 
represents approximately 10% and 25% of total AR expression in non-failing and 
failing human myocardium, respectively [30]. However, the potential poorer 
scintigraphic contrast resulting from AMI9 and AMI9S binding to -AR and due 
to a higher number of targets (vessels, atria, platelets) does not theoretically 
constitute constraints for in vivo quantification of -AR in SPECT because Bmax 
determination will mostly depend upon the highly specific nature of the cold 
ligand used to study nonspecific binding. In addition, the IC50 of AMI9 for [
3
H]-
prazosin and [
3
H]-yohimbin to NRCM was 2.2.10
-5
 M and 1.2.10
-5
 M, 
respectively (data not shown), whereas this value reached 1.9.10
-6
 M when [
3
H]-
CGP12177 was used (Table 1), indicating that AMI9 had a much lower affinity 
for α–AR than for β–AR. AMI9 binding to -AR should therefore represent a 
minimal confounding actor while quantifying -AR density from scintigraphic 
images.  
-AR imaging should avoid the use of -AR agonists due to subsequent 
alterations in receptor conformation, binding dissociation, activation of 
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intracellular reactions and consequently -AR regulation mechanisms. Ligands 
should therefore display high -blocking potency without inner sympathomimetic 
activity. AMI9 and AMI9S demonstrated such properties in isolated perfused rat 
hearts. Indeed, both compounds inhibited the 10 nM isoproterenol-induced 
increase in contractility with a similar potency to that of propranolol without 
causing alterations in cardiac contractility when perfused alone at 1 µM (data not 
shown).  
[3H]-CGP-12177 and [125I]-ICYP behaved as expected in in vivo mouse 
biodistribution studies. ICYP bound more than CGP-12177 to most tissues, likely 
due to the high lipophilicity of the former compound and therefore to its ability to 
bind to nonspecific targets as well as to all β-AR whereas the more hydrophilic 
CGP-12177 only bound to membrane receptors, resulting in lower heart uptake. 
[
3
H]-CGP-12177 and [125I]-ICYP cardiac activities that were obtained in mice in 
the present study were consistent with previously published data in rats when 
considering the differences in heart-to-weight ratios between these 2 species [31]. 
The early cardiac washout of [
125
I]-AMI9 and [
125
I]-ICYP was higher than that of 
[
3
H]-CGP12177 and the results did not seem to indicate that binding affinity 
represented a major determinant of the early in vivo cardiac kinetics of 
radiolabelled β-AR-specific ligands. Indeed, an order of magnitude was observed 
between the Kd of [
125
I]-AMI9 and that of [
125
I]-ICYP (5.6 and 0.4 nM, 
respectively), yet both tracers exhibited a similar cardiac washout of ~60% over 
the first 15 min following injection which was much greater than that of [
3
H]-
CGP12177 (~15%) whereas the latter had a Kd roughly similar to that of [
125
I]-
13 
 
ICYP (1 nM). Linear relationships have been described between the lipophilicity 
of compounds and their respective binding to plasma proteins [32]. A hypothesis 
that might account for greater early cardiac washout of [
125
I]-AMI9 and [
125
I]-
ICYP than [
3
H]-CGP12177 could therefore be that the more lipophilic nature of 
[
125
I]-AMI9 & [
125
I]-ICYP (log(P) = 0.61 and 1.26, respectively) when compared 
to that of [
3
H]-CGP12177 (log(P) = -0.52) resulted in increased cardiac washout 
through increased binding to plasma proteins.  
 [125I]-AMI9 biodistribution showed a significantly lower lung activity than that 
of the more lipophilic [125I]-ICYP from 5 min p.i. Interestingly, [125I]-AMI9 
lung activity was similar to that of the hydrophilic [3H]-CGP-12177 in the first 5 
min following injection and lower afterwards, reaching a CGP-12177/AMI9 DUR 
ratio of 4.7 at 90 min p.i. The moderate in vivo lung activity of AMI9 represents a 
favorable feature for high quality cardiac imaging. Considering the fact that [
11
C]-
CGP12177 has been used clinically with no reports of lung activity impairing 
image acquisition and quantification, and since [
125
I]-AMI9 lung uptake is lower 
than that of [
3
H]-CGP12177, we believe that our results suggest that the 
pulmonary activity of [
125
I]-AMI9 that was observed in the present study is 
suitable for further evaluation of the tracer in the clinical setting.  
Moreover, the fact that [
125
I]-AMI9 cardiac activity was ~1.5 to 2-fold higher than 
that of [
3
H]-CGP12177 in the first 15 min following injection and [
125
I]-AMI9 
blood activity was 17-35% lower than that of [
3
H]-CGP12177 between 1 and 15 
min post-injection resulting in superior early heart-to-blood ratios for [
125
I]-AMI9 
whereas [
3
H]-CGP12177 ratios were slightly superior afterwards. of the 
14 
 
tracersThese results suggests that the potential for in vivo -AR density imaging 
with AMI9 should be further evaluated with special emphasis on early post-
injection time points. 
 
Conclusion 
The iodinated -blocker analog of practolol AMI9 as well as its S enantiomer 
AMI9S exhibited high affinity for -AR in vitro and ex vivo together with 
moderate lipophilicity. AMI9 is a promising iodinated ligand for the in vivo 
assessment of myocardial -adrenoceptor density which requires further clinical 
evaluation.  
 
New Knowledge Gained 
Pathophysiological modifications in β-AR density have been observed in heart 
failure and diabetic heart disease. Although studies using [
11
C]-CGP12177 have 
provided proof-of-concept that β-AR imaging has great potential clinical interest, 
the development of an [
11
C]-labelled PET imaging agent is limited by the 
extremely short half-life of the isotope. The present study showed that the 
iodinated -blocker analog of practolol AMI9 as well as its S enantiomer AMI9S 
exhibited high affinity for -AR in vitro and ex vivo together with moderate 
lipophilicity and that both compounds are therefore promising iodinated ligands 
for the in vivo assessment of myocardial -adrenoceptor density.  
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FIGURE CAPTIONS 
 
Figure 1  
Chemical structure of AMI 9.  
 
Figure 2  
Competition curves for binding to membrane -adrenoceptors from newborn rat 
cardiac myocytes. a, AMI9 vs [
3
H]-CGP-12177; b, AMI9S vs [
3
H]-CGP-12177. 
 
Figure 3  
Scatchard curves indicating saturation of newborn rat cardiac myocyte -
adrenoceptors by [
125
I]-AMI9 (a) and [
125
I]-AMI9S (b). Bound = specifically 
bound radioligand (fmol/mg protein); F = free radioligand (M). Nonspecific 
binding was assessed with 25 µM (±)-propranolol. 
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Compound KI (M) IC50 (M) RBA 
Atenolol (1.1±0.2)x10
-6
 6.9x10
-6
 35.6 
Metoprolol (3.9±0.5)x10
-7
 2.4x10
-6
 12.6 
AMI9 (3.0±0.5)x10
-7
 1.9x10
-6
 9.7 
AMI9S (1.8±0.3)x10
-7
 1.1x10
-6
 5.9 
Propranolol (3.1±0.8)x10
-8
 1.9x10
-7
 1.0 
Alprenolol (1.9±0.2)x10
-8
 1.2x10
-7
 0.6 
Timolol (1.7±0.3)x10
-8
 1.1x10
-7
 0.6 
Pindolol (7.9±1.0)x10
-9
 4.9x10
-8
 0.3 
TABLE 1. KI, IC50 and relative binding affinity [RBA, (KIcompound/KIpropranolol)] 
values of AMI9, AMI9S, and a series of reference -blockers as obtained from 
[
3
H]-CGP-12177 displacement experiments on newborn rat cardiac myocytes. 
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  [
125
I]-AMI9  [
125
I]-AMI9S 
  KI 1 (M) KI 2 (M)  KI 1 (M) KI 2 (M) 
CGP-20712A (  (3.8±2.8)x10
-10
 (2.2±1.1)x10
-7
  (8.1±7.0)x10
-10
 (3.1±0.8)x10
-7
 
ICI 118551 (  (1.1±0.2)x10
-6
 (2.7±1.0)x10
-9
  (1.7±0.8)x10
-7
 (1.5±1.0)x10
-9
 
Prazosin (  (1.1±1.0)x10
-9
 (3.7±1.7)x10
-6
  (8.3±3.4)x10
-9
 (3.8±1.3)x10
-6
 
Yohimbine (  ˜ 10
-3
 (4.7±0.9)x10
-9
  ˜ 10-3 (5.5±0.7)x10-9 
Atropine (musc.)  NC NC  NC NC 
TABLE 2. KI values of selective inhibitors from displacement experiments of [
125
I]-AMI9 and [
125
I]-AMI9S 
binding on newborn rat cardiac myocytes. KI 1 and KI 2 refer to KI values for either the 1/1 or the 2/2 
receptor subtypes. Musc., muscarinic; NC, no competition.  
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TABLE 3. Dose-dependent inhibitory effects of propranolol, AMI9 and AMI9S on the dP/dt max of isolated rat 
hearts stimulated by 10 nM isoproterenol; dP/dt max values (mmHg/sec) expressed as mean ± SD; P value refers 
to the comparison between control perfusion (isoproterenol continuously) and continuous co-perfusions of 
isoproterenol + tested compound. 
Compound Dose (mol/L) n 
dP/dt max 
Baseline 
dP/dt max 
Isoproterenol 
dP/dt max 
co-perfusion 
% inhibition 
P value  
None 
(Control) 
 6 715±325 2535±1233 2398±1088 5.5±11.6  
 10
-10
 6 797±195 2949±341 2857±425 4.7±14.4 0.53 
 10
-9
 6 1017±245 2529±293 2223±176 20.9±7.5 0.40 
Propranolol 10
-8
 6 837±176 2170±325 1271±200 67.5±14.5 0.007 
 10
-7
 6 1004±144 2586±266 926±256 105.9±11.5 0.0001 
 10
-6
 9 941±363 2830±910 767±218 111.5±14.6 0.0001 
 10
-5
 4 905±361 1854±328 156±130 toxic 0.0002 
 10
-10
 6 1101±263 2727±313 2581±277 9.1±3.6 0.83 
 10
-9
 6 991±347 2277±452 1653±456 47.1±13.5 0.029 
AMI9 10
-8
 6 1139±322 2742±237 1371±346 85.2±9.2 0.002 
 10
-7
 4 1304±168 3107±118 1412±214 93.8±5.2 0.003 
 10
-6
 7 1275±195 2758±679 1013±243 116.1±10.3 0.0001 
 10
-5
 6 889±113 2051±644 805±145 109.2±5.4 0.0006 
 10
-10
 5 1686±255 3410±431 3390±498 0.8±8.1 0.96 
 10
-9
 5 1137±132 2198±557 1840±514 38.7±14.0 0.060 
AMI9S 10
-8
 5 1033±216 2050±368 1507±352 55.6±13.6 0.015 
 10
-7
 5 857±215 2152±520 1041±212 85.6±4.1 0.004 
 10
-6
 5 1139±291 2194±700 1180±247 95.5±5.3 0.004 
 10
-5
 4 864±122 1894±388 785±144 108.5±9.1 0.003 
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Time post-
injection (min) 
Heart 
 
Lung 
 
Liver 
 
Kidney 
 
Brain 
 
Muscle 
 
Blood 
 
Fat 
 
0.5 4.7±2.3 14.7±12.1 3.3±2.7 8.9±7.2 0.2±0.1 0.6±0.5 3.1±0.1 0.2±0.1 
1 4.7±2.3 13.9±9.5 3.6±2.5 12.5±8.8 0.2±0.1 0.7±0.4 1.3±0.5 0.2±0.1 
2 5.3±0.5 13.7±2.1 5.2±0.1 12.0±1.6 0.1±0.0 1.2±0.0 1.3±0.2 0.3±0.0 
5 4.2±0.5 9.8±0.6 5.9±1.1 11.0±3.2 0.1±0.0 1.2±0.3 1.3±0.4 0.3±0.0 
10 2.6±0.5 5.6±1.5 3.9±0.5 6.5±2.6 0.1±0.0* 1.0±0.2 1.5±0.5 0.3±0.0 
15 1.8±0.1* 4.7±0.5 2.8±0.2 4.7±1.4 0.1±0.0* 1.1±0.0 1.3±0.1 0.5±0.1* 
30 0.9±0.2* 3.2±0.3 1.8±0.2 2.2±0.4 0.1±0.0* 0.6±0.0 1.2±0.2 0.2±0.0 
45 0.6±0.1* 3.9±0.3 1.3±0.1 1.6±0.1 0.1±0.1 0.5±0.0 1.0±0.3 0.3±0.1 
60 0.5±0.1* 2.7±0.3 1.0±0.1 1.2±0.1 0.1±0.0* 0.4±0.0 1.2±0.5 0.1±0.0 
90 0.5±0.1* 2.3±0.5 0.8±0.1 1.0±0.2 0.3±0.2 0.3±0.1 1.3±0.2 0.1±0.0 
120 0.5±0.1* 2.0±0.3 0.7±0.2 1.3±0.5 0.1±0.0 0.3±0.1 1.1±0.1 0.1±0.0 
TABLE 4. Organ biodistribution of [
125
I]-AMI9 in mice. Values expressed as mean ± SD of DUR. * P < 0.05 vs. 1 min. 
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Time post-
injection (min) 
Heart 
 
Lung 
 
Liver 
 
Kidney 
 
Brain 
 
Muscle 
 
Blood 
 
Fat 
 
0.5 2.5±0.2 14.3±0.6 0.5±0.1 2.7±0.8 0.2±0.1 0.9±0.1 2.2±0.2 0.1±0.1 
1 2.5±0.2 12.9±1.2 0.6±0.0 3.0±1.3 0.1±0.0 0.7±0.1 1.7±0.1 0.2±0.0 
2 2.4±0.2 17.1±1.1* 0.7±0.1* 1.6±0.3 0.1±0.0 0.5±0.2 1.9±0.4 0.4±0.5 
5 2.3±0.4 12.3±4.3 0.7±0.2 1.0±0.2* 0.1±0.0 0.5±0.1* 1.9±0.2 0.1±0.0 
10 1.9±0.4* 11.1±0.7 0.6±0.1 1.1±0.2 0.2±0.0 0.7±0.1 1.8±0.1 0.3±0.3 
15 2.1±0.4 9.8±2.5 0.7±0.1 0.8±0.1* 0.1±0.0 0.8±0.1 2.0±0.0* 0.2±0.0 
30 1.5±0.1* 9.9±0.4* 0.4±0.7 0.7±0.1* 0.1±0.1 0.5±0.1* 1.2±0.2* 0.2±0.1 
45 1.3±0.3* 8.3±2.1* 0.4±0.1 0.5±0.2* 0.1±0.0* 0.5±0.3 0.8±0.1* 0.2±0.2 
60 1.3±0.3* 9.9±1.4* 0.4±0.1* 0.6±0.1* 0.1±0.0* 0.5±0.0* 0.9±0.1* 0.6±0.6 
90 1.1±0.2* 10.7±0.8* 0.4±0.0* 0.5±0.1* 0.0±0.0* 0.4±0.1* 0.7±0.1* 0.1±0.1* 
120 0.9±0.2* 7.9±1.4* 0.3±0.0* 0.4±0.1* 0.0±0.0* 0.5±0.1* 0.6±0.1* 0.1±0.1 
TABLE 5. Biodistribution pattern of [
3
H]-CGP-12177 in mice. Values expressed as mean ± SD of DUR. * P < 0.05 vs. 1 min. 
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Time post-
injection (min) 
Heart 
 
Lung 
 
Liver 
 
Kidney 
 
Brain 
 
Muscle 
 
Blood 
 
Fat 
 
0.5 4.7±1.5 23.4±3.5 3.4±0.3 10.1±1.3 0.1±0.0 0.7±0.0 2.6±0.4 0.1±0.0 
1 4.9±0.7 24.8±13.6 2.9±0.2 8.6±0.7 0.1±0.0 0.8±0.3 1.8±0.3 0.2±0.1 
2 4.1±0.4 23.4±7.0 3.1±0.6 6.9±1.2 0.1±0.0 0.6±0.1 2.4±0.4 0.3±0.3 
5 3.3±0.8* 27.7±4.8 2.7±0.1 8.8±0.4 0.1±0.0 0.5±0.2 2.2±0.6 0.3±0.3 
10 2.4±0.4* 35.2±6.8 1.7±0.1* 5.1±0.3* 0.1±0.0 0.5±0.1 2.4±0.1* 0.6±0.1* 
15 2.2±0.8* 24.6±0.0 2.0±0.6 6.0±0.8* 0.1±0.0 0.5±0.1 1.9±0.6 0.2±0.0 
30 2.1±0.2* 26.9±5.6 1.5±0.1* 5.0±0.8* 0.1±0.0 0.6±0.1 2.3±0.1* 0.3±0.1 
45 1.8±0.2* 34.8±8.3 1.1±0.1* 4.5±0.5* 0.1±0.0 0.5±0.1 2.7±0.7 0.3±0.1 
60 2.2±0.5* 32.5±8.5 1.0±0.1* 2.2±0.2* 0.1±0.0 0.6±0.2 1.7±0.5 0.1±0.0 
90 2.2±0.3* 34.3±7.3 1.1±0.2* 2.5±0.5* 0.1±0.0 0.5±0.1 1.8±0.5 0.4±0.3 
120 2.1±0.2* 18.2±1.8 1.1±0.2* 1.9±0.1* 0.1±0.0 0.7±0.1 1.9±0.1 0.1±0.1 
TABLE 6. Biodistribution pattern of [
125
I]-ICYP in mice. Values expressed as mean ± SD of DUR. * P < 0.05 vs. 1 min. 
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